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MaOBJECTIVES The aim of this study was to determine the incidence, causes, and predictors of unplanned hospital
readmissions after transcatheter aortic valve replacement (TAVR).
BACKGROUND Data regarding unplanned hospital readmissions after TAVR in a real-world all-comers population are
scarce.
METHODS A total of 720 consecutive patients undergoing TAVR at 2 centers who survived the procedure, were included.
Median follow-up was 23 months (interquartile range [IQR]: 12 to 39 months), available in 99.9% of the initial population.
The occurrence, timing, and causes of hospital readmission within the ﬁrst year post-TAVR were obtained in all cases. Early
and late readmissions were deﬁned as those occurring #30 days and >30 days to 1 year post-TAVR, respectively.
RESULTS There were 506 unplanned readmissions in 316 patients (43.9%) within the ﬁrst year post-TAVR (median time:
63days; IQR:19to158dayspost-discharge).Ofthese,early readmissionoccurred in105patients (14.6%),and118patients (16.4%)
hadmultiple ($2) readmissions. Readmissions were due to noncardiac and cardiac causes in 59% and 41% of cases, respectively.
Noncardiac readmissions included, in order of decreasing frequency, respiratory, infection, andbleedingevents as themain causes,
whereas heart failure and arrhythmias accounted for most cardiac readmissions. The predictors of early readmission were peri-
proceduralmajor bleeding complications (p¼0.001), anemia (p¼0.019), lower left ventricular ejection fraction (p¼0.042), and
the combined presence of antiplatelet and anticoagulation therapy at hospital discharge (p¼ 0.014). The predictors of late
readmissionwere chronic obstructivepulmonarydisease (p¼0.001), peripheral vascular disease (p¼0.023), chronic renal failure
(p¼ 0.013), and atrial ﬁbrillation (p¼ 0.012). Early readmission was an independent predictor of mortality during the follow-up
period (hazard ratio: 1.56, 95% conﬁdence interval: 1.02 to 2.39, p¼ 0.043).
CONCLUSIONS The readmission burden after TAVR in an all-comers population was high. Nearly one-ﬁfth of the
patients were readmitted early after hospital discharge, increasing the risk of mortality at follow-up. Reasons for
readmission were split between noncardiac and cardiac causes, with respiratory causes and heart failure as the main
diagnoses in each group, respectively. Whereas early readmissions were mainly related to periprocedural bleeding
events, most late readmissions were secondary to baseline patient comorbidities. These results underscore the impor-
tance of and provide the basis for implementing speciﬁc preventive measures to reduce readmission rates after TAVR.
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AB BR E V I A T I O N S
AND ACRONYM S
CI = conﬁdence interval
HR = hazard ratio
IQR = interquartile range
TAVR = transcatheter aortic
valve replacement
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1749U nplanned readmissions after initial hospi-talization are frequent, signiﬁcantly af-fecting clinical outcomes, patient quality
of life, and health care costs (1,2). Early (within
30 days of discharge) readmissions have generated
signiﬁcant debate. As many as 20% of Medicare bene-
ﬁciaries are readmitted within 30 days after an index
hospitalization, and this has been associated with
additional health care costs exceeding $15 billion (1).
Of note, the rate of early unplanned readmissions
has been considered a marker of quality of care
and hospital performance (3,4), and the subject
of provider payment restrictions in the United
States. Identifying the timing, causes, and predictors
of unplanned readmissions is thus fundamental
for implementing appropriate preventive measures.
Transcatheter aortic valve replacement (TAVR) is
currently the standard treatment for severe aortic
stenosis in symptomatic patients with prohibitive or
high surgical risk (5). The signiﬁcant burden of
comorbidities in patients currently undergoing
TAVR, as well as the relatively high rate of peri-
procedural complications, engenders a high likeli-
hood of hospital readmissions in such patients.
However, data on unplanned readmissions after
TAVR are scarce, particularly regarding the timing,
speciﬁc causes, and predictors of readmission. More
importantly, no data exist on 30-day readmissions
after TAVR apart from reporting its incidence (6–8).
The objectives of this study were to determine the
incidence, causes, and predictive factors of un-
planned hospital readmissions after TAVR, with a
speciﬁc focus on readmissions within the 30-day and
1-year periods.
METHODS
STUDY POPULATION. A total of 893 consecutive pa-
tients with symptomatic severe aortic stenosis who
underwent TAVR at 2 centers were evaluated for the
study. Of these, patients who died before hospital
discharge (n ¼ 65) or those with follow-up of less than
1 year (n ¼ 108) were excluded, leading to a ﬁnal
population of 720 patients. The indications for TAVR
and procedural approach were assessed by each cen-
ter’s heart team composed of interventional cardiol-
ogists and cardiac surgeons. The TAVR procedures
were performed using balloon- and self-expanding
valves, as previously described (5). In-hospital
and follow-up data were prospectively entered in a
dedicated database. Clinical outcomes were deﬁned
according to Valve Academic Research Consortium-2
criteria (9). All patients signed informed consentforms before the procedure, and all studies
were performed in accordance with the local
ethics committee of each center.
FOLLOW-UP. Clinical follow-up was carried
out during pre-scheduled outpatient clinic
visits or by telephone contact at 1, 6, and
12 months post-TAVR and yearly thereafter.
Records from referring cardiologists, general
practitioners, and other hospitals were consulted
whenever necessary for further information. Com-
plete information about readmissions within the last
follow-up was obtained in 99.9% of patients (1 patient
was lost to follow-up). The median length of follow-
up of the study population was 23 months (inter-
quartile range [IQR]: 12 to 39 months).
HOSPITAL READMISSION. Readmissions were de-
ﬁned as a patient being admitted to a hospital ward
or an intensive care unit. Visits to the emergency
department or admission to a day-stay hospital were
excluded from the current analysis. Readmission
date, duration of hospital stay, primary and second-
ary reasons for hospitalization, and in-hospital death
were recorded after a detailed medical records re-
view. The primary diagnosis on the discharge report
was used to determine the main cause of read-
mission. Causes of readmission were grouped as be-
ing of cardiac or noncardiac origin. Cardiac causes
included the following: heart failure, acute coronary
syndrome (unstable angina or myocardial infarction),
arrhythmia, and prosthesis related (endocarditis,
valve thrombosis, structural failure of the valve
requiring intervention). Noncardiac causes were
classiﬁed as follows: respiratory (including pneu-
monia), bleeding, cerebrovascular event (ischemic
or hemorrhagic stroke, transient ischemic attack),
peripheral vascular events, infections, trauma, and
other.
Time to readmission was calculated as the time
between the date of hospital discharge after the index
TAVR procedure (time 0) and the ﬁrst hospital read-
mission day. Readmissions were also classiﬁed ac-
cording to the timing as early (#30 days) or late
(between 30 days and 12 months). Multiple read-
missions were deﬁned as $2 readmissions.
STATISTICAL ANALYSIS. Categorical variables were
expressed as number (percentage) and continuous
variables as mean  SD or median (IQR: 25th to 75th
percentiles) according to their distribution. Assess-
ment of normality for continuous data was performed
using the Shapiro-Wilks test. Comparison of numeri-
cal variables was performed with the 2-sided Student
t test or Wilcoxon rank sum test, and the chi-square
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variables. We determined unadjusted all-cause early,
late, and overall readmission rates. Analysis of the
predictors of hospital readmissions was performed
using the conditional Prentice-Williams-Peterson
model (10) to account for multiple events. Variables
with a p value <0.05 on univariate analysis were
entered into a logistic regression analysis to deter-
mine the independent predictors of early, late, and
overall readmissions. Univariate and multivariate
competing-risk (mortality not occurring during a
hospital admission) regression analyses were done to
determine the predictors of readmissions. Freedom
from readmission and mortality curves were calcu-
lated with the Kaplan-Meier method, and comparison
between groups was performed with the log-rank
test. A landmark analysis excluding patients who
died at <30 days was used to further investigate the
impact of early readmission on 2-year mortality. A
p value <0.05 was considered signiﬁcant for all sta-
tistical tests. All data were analyzed with the Statis-
tical Package for Social Sciences version 20.0 (SPSS
Inc., IBM, Armonk, New York) and the R statistical
software, version 3.0.2 (R Foundation for Statistical
Computing, Vienna, Austria).
RESULTS
The main baseline, procedural characteristics, and in-
hospital complications of the study population are
shown in Table 1.
INCIDENCE, TIMING, AND CAUSES OF HOSPITAL
READMISSIONS. A total of 316 patients (43.9%) were
readmitted during the ﬁrst year after the index
TAVR procedure, with a total of 506 readmission
episodes (70.4% total readmissions per index
discharge and 1.6 episodes per admitted patient). A
total of 198 patients (27.5%) experienced 1 read-
mission, and 118 patients (16.4%) had multiple ($2)
readmissions, ranging from 2 to 7. The median time
from the TAVR procedure discharge to the ﬁrst
readmission was 63 days (IQR: 19 to 157 days). The
median length of stay per readmission was 7 (IQR:
4 to 13 days).
The timing of hospital readmission within the year
after TAVR is shown in Figure 1. Early (#30 days)
readmission occurred in 105 patients (14.6%) with
115 readmission episodes (10 patients had 2 read-
missions). This represented 33.2% of total readmitted
patients within the year after TAVR. As many as 41
patients (5.7%) were readmitted within the 7 days
after TAVR. A total of 88 patients were readmitted
between 30 days and 3 months, leading to a read-
mission rate of 26.8% within the 3 months afterTAVR. An additional 123 patients (17.1%) required
hospital readmission between 3 and 12 months after
TAVR.
The causes of readmission within the ﬁrst year
are summarized overall and according to timing in
Table 2. Of 506 readmission episodes, 298 (58.9%)
were due to noncardiac causes, mostly respiratory
(20.1%), infection (15.4%), and bleeding (12.1%)
events. Cardiac origin accounted for 208 readmission
episodes (41.1%), mainly due to heart failure (56.7%)
and arrhythmic events (21.2%). Bradyarrhythmias
accounted for 18 events, and tachyarrhythmias ac-
counted for 28 events (17 atrial arrhythmias and 9
ventricular arrhythmias). One-fourth of readmissions
due to cardiac reasons required an invasive procedure.
Early readmissions were also predominantly
noncardiac in origin (57.4%), secondary to infections
(18.2%, mainly access-site infections) and respiratory
(16.7%) or bleeding (15.1%) events. Cardiac causes
accounted for 42.6% of early readmissions, with the
vast majority of patients being readmitted because of
heart failure (71.4%). There were no differences be-
tween the main causes (cardiac vs. noncardiac) of
early and late readmission after TAVR (p ¼ 0.71).
However, from the perspective of cardiac etiology–
driven readmissions, heart failure was more fre-
quently a cause of early instead of late readmission
(p ¼ 0.018).
The Kaplan-Meier curves of readmission events
(patient based) over time overall and according to the
underlying causes (cardiac vs. non-cardiac) are shown
in Figure 2.
PREDICTORS OF HOSPITAL READMISSION. The
predictors of early and late hospital readmission after
TAVR are shown in Tables 3 and 4, respectively. The
independent predictors of early readmissions were
procedural complications deemed major or life-
threatening bleeding (hazard ratio [HR]: 2.41, 95%
conﬁdence interval [CI]: 1.57 to 3.70; p ¼ 0.001), left
ventricular ejection fraction (HR: 1.08 for each
decrease of 5%, 95% CI: 1.00 to 1.17; p ¼ 0.042),
hemoglobin levels (HR: 1.19 for each decrease of
1 g/dl, 95% CI: 1.03 to 1.39; p ¼ 0.019), and com-
bination antithrombotic therapy (anticoagulation þ
antiplatelet) (HR: 1.62, 95% CI: 1.10 to 2.39; p ¼ 0.014)
at hospital discharge. The independent predictors of
late readmissions were chronic obstructive pulmo-
nary disease (HR: 1.49, 95% CI: 1.21 to 1.84; p ¼ 0.001),
atrial ﬁbrillation (HR: 1.32, 95% CI: 1.06 to 1.63;
p ¼ 0.012), peripheral vascular disease (HR: 1.29,
95% CI: 1.04 to 1.61; p ¼ 0.023), and renal function at
hospital discharge (HR: 1.05 for each eGFR decrease of
10 ml/min, 95% CI: 1.01 to 1.09; p ¼ 0.013). The factors
independently associated with multiple ($2 vs. 1)
FIGURE 1 Percentage of Unplanned Hospital Readmissions After TAVR
The percentage of readmitted patients and number of readmission episodes within the year
after TAVR, grouped according to the timing of readmission. TAVR ¼ transcatheter aortic
valve replacement.
TABLE 1 Baseline Clinical and Procedural Characteristics and
In-Hospital Outcomes of the Study Population (N ¼ 720)
Baseline variables
Age, yrs 82 (77-86)
Male 301 (41.8)
Body mass index, kg/m2 27.3  5.3
NYHA functional class
I–II 186 (25.8)
III–IV 534 (74.1)
Diabetes 241 (33.5)
Hypertension 614 (85.3)
Coronary artery disease 412 (57.2)
Previous CABG 194 (26.9)
Atrial ﬁbrillation (chronic/paroxysmal) 239 (33.2)
Previous pacemaker 88 (12.2)
Previous stroke 112 (15.6)
Peripheral vascular disease 178 (24.7)
COPD 179 (24.9)
eGFR <60 ml/min 364 (50.6)
Logistic EuroSCORE 16.6 (10.1–25-0)
Echocardiographic variables
LVEF, % 55.1  14.6
Mean aortic gradient, mm Hg 43.0  16.4
Aortic valve area, cm2 0.60 (0.50–0.77)
Procedural characteristics
Approach
Transfemoral 481 (66.5)
Not transfemoral 239 (33.2)
Prosthesis type
Balloon-expandable 609 (84.6)
Self-expandable 111 (15.4)
Prosthesis size, mm
#23 301 (41.8)
24–28 281 (39.0)
$29 133 (18.5)
In-hospital complications
Need for a second valve 25 (3.5)
Conversion to open heart surgery 16 (2.2)
New permanent pacemaker 76 (10.6)
New persistent left bundle branch block 95 (13.2)
Stroke 17 (2.4)
Major vascular complication 60 (8.3)
Major or life-threatening bleeding 98 (13.6)
Acute kidney injury 144 (20.0)
Echocardiographic variables at hospital discharge
LVEF, % 55.6  13.0
Mean aortic gradient, mm Hg 10.6  6.1
Aortic regurgitation (moderate-severe) 54 (7.5)
Mitral regurgitation (grades 3–4) 70 (9.7)
Treatment at hospital discharge
None 12 (1.7)
Single antiplatelet therapy 95 (13.2)
Dual antiplatelet therapy 338 (46.9)
Single anticoagulation therapy 50 (6.9)
Antiplatelet þ anticoagulation therapy 202 (28.1)
Hospitalization length, days 7 (5–9)
Values are median (interquartile range), n (%), or mean  SD.
CABG ¼ coronary artery bypass graft; COPD ¼ chronic obstructive pulmonary
disease; eGFR ¼ estimated glomerular ﬁltration rate; LVEF ¼ left ventricular
ejection fraction; NYHA ¼ New York Heart Association.
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1751readmissions within 1 year were lower mean gradient
at baseline (HR: 1.08, 95% CI: 1.02 to 1.15; p ¼ 0.011)
and major or life-threatening bleeding (HR: 2.36,
95% CI: 1.50 to 3.71; p ¼ 0.001).
READMISSIONS AND MORTALITY. A total of 44 pa-
tients (13.9%) died during a readmission episode (25
of them [7.9%] during the ﬁrst readmission episode).
In a sensitivity analysis, we evaluated the impact
of 30-day readmissions on 30-day to 2-year mortality.
The mortality rate at 2-year follow-up was 20.8%
(95% CI: 17.5% to 24.1%). In those patients readmitted
within 30 days after TAVR, the mortality rate at 2
years was 30.2% (95% CI: 20.4% to 40.0%) compared
with 19.2% (95% CI: 15.7% to 22.7%) in those without
30-day readmission (log-rank p ¼ 0.002) (Figure 3).
Early readmission was a factor associated with a
higher mortality rate (30-day to 2-year) (HR: 1.89, 95%
CI: 1.25 to 2.87; p ¼ 0.003), and this association per-
sisted after adjusting for confounding factors in a
multivariable analysis (Table 5).
DISCUSSION
Almost one-half of the patients undergoing TAVR
were readmitted within the ﬁrst year after the pro-
cedure, and about one-fourth of such readmissions
occurred within the ﬁrst 30 days post-TAVR (30-day
readmission rate, w15%). Multiple readmissions
were observed in more than one-third of such pa-
tients. Most (w60%) readmissions were due to
noncardiac causes, with respiratory failure, infection,
TABLE 2 Causes of Hospital Readmission Within the Year After TAVR, Overall and
According to the Timing of Readmission
Causes of Readmission
Overall,
1 Year
(n ¼ 506)
Early,
#30 Days
(n ¼ 115)
Late,
30–365 Days
(n ¼ 391)
Cardiac causes 208 (41.1) 49 (42.6) 159 (40.7)
Heart failure 118 (23.3) 35 (30.4) 83 (21.2)
Arrhythmia 44 (8.7) 11 (9.6) 33 (8.4)
Bradyarrhythmia 18 2 16
Ventricular arrhythmia 9 3 6
Rapid atrial/ﬂutter ﬁbrillation 17 6 11
Acute coronary syndrome 27 (5.3) 2 (1.7) 25 (6.4)
Myocardial infarction 17 1 16
Unstable angina 10 1 9
Prosthesis related 19 (3.7) 1 (0.9) 18 (4.6)
Endocarditis 12 1 11
Valve thrombosis 2 0 2
Total events requiring an invasive
cardiac procedure
50 (9.9) 7 (6.1) 43 (11.0)
Pacemaker implantation 18 3 15
Cardioverter deﬁbrillator implantation 5 1 4
Repeat coronary angiography or PCI 14 1 13
Prosthesis intervention
(surgery/percutaneous)
5 0 5
Arrhythmia ablation 4 1 3
Upgrade to cardiac resynchronization
therapy
1 0 1
Thoracocentesis 1 0 1
Mitral valve surgery 1 0 1
Continued on the next page
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1752and bleeding events accounting for more than one-
half of such events. Approximately 40% of read-
missions were secondary to cardiac causes, with heart
failure accounting for more than one-half of such
cases. Readmissions requiring prosthetic valve rein-
tervention were infrequent. Although periprocedural
bleeding complications, anemia, lower left ventricu-
lar ejection fraction, and more intensive antith-
rombotic treatment regimen on hospital discharge
were the main predictors of 30-day readmissions,
baseline comorbidities such as chronic obstructive
pulmonary disease, renal failure, peripheral vascular
disease, and atrial ﬁbrillation identiﬁed a group of
patients with a higher likelihood of delayed read-
mission. Patients requiring early rehospitalization
had a higher mortality risk during the follow-up
period.
Several studies have evaluated 30-day readmission
rates after cardiac interventions. These ranged from
9% to 24% after percutaneous coronary interventions
and cardiac surgery (11–16). In patients undergoing
isolated aortic valve replacement, the 30-day read-
mission rates werew20% (16), marginally higher than
the 15% rate observed in our study. According to our
ﬁndings, Holmes et al. (6) reported a 30-day read-
mission rate of 17% in a large series of real-worldconsecutive patients who underwent TAVR in the
TVT (Transcatheter Valve Therapies) registry. At
1-year follow-up, the readmission rate increased to
nearly 50%, similar to the 44% reported in the present
analysis. In addition, we report for the ﬁrst time that
as many as one-third of patients requiring hospital
readmission post-TAVR are in fact hospitalized on
multiple occasions (mean, 2.6  1.0) within the year
after TAVR. This represents a signiﬁcant readmission
burden, much higher than those observed in previous
studies involving cardiac interventions (17) and close
to those observed after heart failure hospitalizations
(18,19). The additional costs associated with such a
high rehospitalization rate may lead some to question
the cost-effectiveness of TAVR in an all-comers
setting. These data suggest the need to better deﬁne
risk factors associated with post-TAVR readmissions
to implement appropriate preventive strategies.
CAUSES OF HOSPITAL READMISSION POST-TAVR.
The reasons for repeat hospitalization after TAVR
were diverse and included a broad of range of cardiac
and noncardiac etiologies. Noncardiac causes repre-
sented the main reason for hospital readmissions in
w60% of patients, and respiratory, infection, and
bleeding-related events accounted for approximately
one-half of such readmissions. These rates mimic
those reported for mortality causes in TAVR patients
(20–23) and highlight the importance of comorbid
conditions in this population. Pneumonia has been
described as the most frequent cause of noncardiac
readmission after hospital discharge (1) and was also
the most common noncardiac cause for hospital
readmission in the present analysis. Other infections,
predominantly access site and genitourinary, were
also frequent. Special attention to proven strategies
for reducing respiratory and access-site infections
may be critical to improve readmission rates (24,25).
Furthermore, bleeding (mostly gastrointestinal) and
vascular events were important factors related to
hospital readmission. It has been shown that major
late bleeding events are a strong predictor of late
mortality after TAVR and increase the risk of reho-
spitalization (26). This underscores the difﬁculties
in selecting the most appropriate antithrombotic
treatment in this elderly and high-risk population,
emphasizing the cautionary use of overly aggressive
antithrombotic regimens (27). Finally, although
readmissions due to traumatic causes were relatively
infrequent, post-discharge rehabilitation programs
to improve physical ﬁtness and avoid falls and frac-
tures in this frail population may be of the utmost
importance as a preventive strategy as well as for
improving patients’ quality of life.
TABLE 2 Continued
Causes of Readmission
Overall,
1 Year
(n ¼ 506)
Early,
#30 Days
(n ¼ 115)
Late,
30–365 Days
(n ¼ 391)
Noncardiac causes 298 (58.9) 66 (57.4) 232 (59.3)
Respiratory 60 (11.9) 11 (9.6) 49 (12.5)
Pneumonia 29 6 23
Upper respiratory tract infection 17 3 14
COPD exacerbation or respiratory
failure
9 1 8
Others 5 1 4
Infection 46 (9.1) 12 (10.4) 34 (8.7)
Access site 15 7 8
Genitourinary 11 1 10
Gastrointestinal 7 2 5
Bacteremia without endocarditis 4 0 4
Other 9 2 7
Bleeding 36 (7.1) 10 (8.7) 26 (6.7)
Gastrointestinal 29 8 21
Access site 2 1 1
Genitourinary 2 1 1
Others 3 0 3
Peripheral vascular event 26 (5.1) 7 (6.1) 19 (4.9)
Arterial limb event 15 5 10
Pulmonary thromboembolism 5 1 4
Vein limb event 3 0 3
Others 3 1 2
Cerebrovascular event 26 (5.1) 9 (7.8) 17 (4.3)
Ischemic cerebrovascular event 23 9 14
Intracranial bleeding 3 0 3
Traumatology 26 (5.1) 6 (5.2) 20 (5.1)
Fall 10 3 7
Fractures 12 2 10
Other 78 (15.4) 11 (9.6) 67 (17.1)
Values are n (%) or n.
COPD ¼ chronic obstructive pulmonary disease; PCI ¼ percutaneous coronary intervention;
TAVR ¼ transcatheter aortic valve replacement.
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1753Approximately 40% of unplanned hospital read-
missions after TAVR were due to cardiac causes, and
heart failure accounted for more than one-half of
such rehospitalizations. Importantly, a signiﬁcant
proportion of such readmissions occurred within the
30 days after hospital discharge. Although only one-
ﬁfth of patients undergoing TAVR have a reduced
left ventricular ejection fraction, heart failure re-
mains the most important single cause of mortality
and rehospitalization among TAVR patients (22,28). A
higher left ventricular mass regression post-TAVR has
been reported as an independent factor of late reho-
spitalizations due to heart failure (8). This suggests an
important role for diastolic dysfunction in such
patients and underscores the importance of inter-
vening before excessive ventricular hypertrophy and
advanced ﬁbrosis occurs. It has been shown that the
vast majority of patients undergoing TAVR have
elevated N-terminal pro–B-type natriuretic peptide
levels irrespective of ventricular function parameters
(29). Also, the high prevalence of comorbidities such
as hypertension, anemia, renal dysfunction, atrial
ﬁbrillation, and concomitant signiﬁcant mitral
regurgitation may also contribute to the high rate of
heart failure rehospitalization after TAVR. Although
we did not ﬁnd an association between signiﬁcant
post-TAVR aortic regurgitation, this factor has been
reported to increase N-terminal pro–B-type natri-
uretic peptide levels and rehospitalization due to
heart failure in previous studies (8,30). This high-
lights the critical role of implementing post-TAVR
programs with closer follow-up similar to those used
for heart failure patients to reduce the rehospitaliza-
tion burden (31,32). Meanwhile, the involvement of
the already well-established heart failure clinics may
represent a very ﬁrst measure to improve outcomes in
these patients.
Cardiac arrhythmias are a well-known factor
for rehospitalization after cardiac surgery (13,33),
representing the second cause of cardiac read-
missions after TAVR in the present study. Interest-
ingly, tachyarrhythmias (mainly atrial ﬁbrillation)
accounted for two-thirds of such cases, whereas
bradyarrhythmias were responsible for one-third of
readmissions due to arrhythmic causes. These data
suggest the extension of the atrial arrhythmia bur-
den beyond the periprocedural period (34), and
emphasize the importance of better establishing the
predictors of late advanced atrioventricular block
requiring pacemaker implantation after TAVR, espe-
cially in patients in whom conduction disturbances
develop after the procedure (28,35,36). Importantly,
although one-fourth of cardiac readmissions re-
quired an invasive procedure (mainly pacemakerimplantation or coronary angiography), only a few
patients required reintervention at the prosthesis
level (balloon post-dilation, paravalvular leak
closure, or implantation of a second valve in most
cases). This is in accordance with previous studies
showing the very low rate of reinterventions or
structural failure associated with transcatheter pros-
theses up to 5-year follow-up (37).
PREDICTORS OF 30-DAY AND LATE HOSPITAL
READMISSION POST-TAVR. The ability to identify
those patients at higher risk of readmission after
TAVR is a critical step for optimizing health care
programs in a cost-efﬁcient manner. Interestingly,
the predictors of 30-day readmission were mainly
related to periprocedural complications (bleeding
events in particular) and treatment at hospital
FIGURE 2 Hospital Readmission Events Within the Year After TAVR
Kaplan-Meier curves showing the readmission events over time, overall, and according to
the main reasons for readmission (cardiac/noncardiac). TAVR ¼ transcatheter aortic valve
replacement.
TABLE 3 Predictors
Predictors
Diabetes
eGFR at hospital discha
ml/min*
Transfemoral approach
Acute kidney injury
(stages 1–3)
Major or life-threatenin
bleeding
LVEF at hospital dischar
Hemoglobin at hospita
discharge, g/dl‡
Signiﬁcant MR at hosp
discharge
Single or dual antiplate
þ anticoagulation t
*For each decrease of 10 m
CI ¼ conﬁdence interval;
in Tables 1 and 2.
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1754discharge, whereas the main factors associated with
later rehospitalizations were patient comorbidities.
Periprocedural major bleeding events remain one
of the most frequent complications of TAVR, andof Early (#30 Day) Hospital Readmission After TAVR
Univariable Multivariable
Analysis,
OR (95% CI) p Value
Analysis,
HR (95% CI) p Value
1.46 (1.01–2.12) 0.043
rge, 1.11 (1.02–1.22) 0.021
0.63 (0.43–0.90) 0.013
1.56 (1.05–2.31) 0.028
g 2.34 (1.55–3.55) <0.001 2.41 (1.57–3.70) <0.001
ge, %† 1.11 (1.04–1.18) 0.002 1.08 (1.00–1.17) 0.042
l 1.26 (1.09–1.44) 0.002 1.19 (1.03–1.39) 0.019
ital 2.03 (1.25–3.28) 0.004
let
herapy
1.85 (1.26–2.72) 0.002 1.62 (1.10–2.39) 0.014
l/min. †For each decrease of 5%. ‡For each decrease of 1 g/dl.
HR ¼ hazard ratio; MR ¼mitral regurgitation; OR ¼ odds ratio; other abbreviations asseveral studies have shown the high impact of such
events on patient survival (26,27,38). It is therefore
not surprising that this periprocedural compli-
cation predicted early readmissions in our study.
Additionally, a lower hemoglobin level at hospital
discharge also played an important role in early
readmissions. In fact, anemia has been well recog-
nized as an important risk factor for hospital read-
mission (39), and we previously showed that the vast
majority of TAVR patients have some degree of ane-
mia at hospital discharge (40). The interaction be-
tween low hemoglobin levels and heart failure
decompensation as well as enhancement of the
symptoms related to any bleeding episode may
represent the most important pathophysiological
links between anemia and early rehospitalization
post-TAVR (41,42). Finally, a more intensive antith-
rombotic treatment consisting of a combination of
anticoagulant and antiplatelet drugs was also associ-
ated with a higher risk of early readmissions. The use
of such antithrombotic combination therapies has
increased the risk of bleeding events after valve sur-
gery, and its risks should be appropriately balanced
against the potential beneﬁts in this high-risk popu-
lation (27). In summary, these results suggest that
reducing periprocedural bleeding events, better
management of anemia before hospital discharge,
and decreasing the intensity of antithrombotic treat-
ment (particularly in patients with high bleeding
risks) may reduce the rates of early rehospitalization
after TAVR. The efﬁcacy of implementing programs
directed at correcting such factors needs to be
demonstrated in future studies.
The risk of late (>30 days) readmission after TAVR
was mainly determined by the presence of atrial
ﬁbrillation, peripheral vascular disease, chronic
kidney disease, and chronic obstructive pulmonary
disease, which have also been systematically found to
be strong mortality risk factors in TAVR (6,22,23).
Lindman et al. (8) also reported an independent as-
sociation between major arrhythmia and late
procedure-related or cardiac readmission. Interest-
ingly, a lower mean gradient at baseline was a factor
determining multiple readmissions in our study.
Multidisciplinary evaluation of these patients is
necessary not only in the patient-selection process,
but also in post-procedure follow-up. These ﬁndings
suggest that implication and evaluation in the im-
mediate outpatient TAVR clinic by other specialized
clinics (e.g., pulmonology, nephrology, geriatricians)
will be essential to improve their outcomes. The
complexity of the comorbidities of the current TAVR
population may require a better selection process and
closer follow-up.
TABLE 4 Predictors of Late (30–365 Days) Hospital Readmission After TAVR
Predictors
Univariable Multivariable
Analysis,
OR (95% CI) p Value
Analysis,
HR (95% CI) p Value
COPD 1.46 (1.18–1.79) <0.001 1.49 (1.21–1.84) <0.001
Peripheral vascular disease 1.37 (1.11–1.70) 0.004 1.29 (1.04–1.61) 0.023
Previous cerebrovascular
disease
1.30 (1.02–1.65) 0.034
Atrial ﬁbrillation (chronic or
paroxysmal)
1.28 (1.04–1.57) 0.019 1.32 (1.06–1.63) 0.012
eGFR at hospital discharge,
ml/min*
1.05 (1.01–1.09) 0.021 1.05 (1.01–1.09) 0.013
LVEF, %† 1.05 (1.02–1.09) 0.005
Single or dual antiplatelet þ
anticoagulation therapy
1.26 (1.02–1.55) 0.032
*For each decrease of 10 ml/min. †For each decrease of 5%.
Abbreviations as in Tables 1 through 3.
FIGURE 3 Early Hospital Readmission After TAVR and Mortality
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1755CLINICAL IMPACT OF EARLY READMISSIONS POST-
TAVR. Previous studies in the surgical ﬁeld have
identiﬁed early readmission as a risk factor for
mortality at follow-up (43). Similar to these studies,
our results also suggest an independent association
between early readmission post-TAVR and poorer
clinical outcomes. Apart from the negative conse-
quences of hospitalization (e.g., risk of nosocomial
infections), early readmission probably identiﬁes a
vulnerable group of patients with a higher risk of
poorer outcomes in the coming months. Future ef-
forts should be made to identify and enhance the
post-discharge health care measures in this group of
patients.
STUDY LIMITATIONS. This study was limited to 2
high-volume TAVR centers, and the results will
need validation in a larger multicenter cohort of pa-
tients. However, readmission rates were similar to
those recently reported in the TVT registry (6) and are
likely representative of the global TAVR population.
No event adjudication committee was available for
this study. However, unlike most previous series
reporting readmission rates on the basis of digital
codes, the principal diagnosis for hospital read-
mission in our study was established on the basis of
the ﬁnal diagnosis at hospital discharge after a
detailed medical record review. There was no sys-
tematic pre-procedural geriatric evaluation of the
patients, and the impact of typical factors on this
population such as frailty or cognitive impairment
was not assessed.Kaplan-Meier survival curves between 30-day and 2-year follow-up for all-cause mortality
after TAVR, according to the occurrence of early (#30 days) hospital readmission. TAVR ¼
transcatheter aortic valve replacement.CONCLUSIONS
The readmission burden in TAVR patients is very high
(almost 50% at 1 year), with almost one-fourth of the
episodes occurring in the early (#30 days) period af-
ter hospital discharge. Noncardiac causes led by res-
piratory, infection, and bleeding events accounted
for nearly two-thirds of readmission episodes,
whereas cardiac causes led by heart failure were
responsible for the remainder of hospitalizations.
Although periprocedural bleeding events, left ven-
tricular ejection fraction, anemia, and intensive
antithrombotic treatment were the main predictors
of early readmissions, patient comorbidities (chronic
obstructive pulmonary disease, peripheral vascular
disease, atrial ﬁbrillation, and renal dysfunction)
were the main factors determining late readmissions.
Early readmission was identiﬁed as an independent
predictor of mortality at 2-year follow-up. These
results delineate, for the ﬁrst time, all types ofreadmission causes post-TAVR and reﬂect the real-
world all-comer readmission burden in this popula-
tion. In addition, they provide the rationale for
implementing speciﬁc health care programs to reduce
readmissions after TAVR. While waiting for the
results of future randomized studies to determine
the most effective strategies to reduce hospital
PERSPECTIVES
WHAT IS KNOWN? Unplanned readmissions after
initial cardiac intervention or hospitalization are
frequent and associated with a signiﬁcant impact on
survival, patient quality of life, and health care costs.
WHAT IS NEW? Almost one-half of the patients
undergoing TAVR were readmitted within 1 year. One-
ﬁfth were readmitted within the ﬁrst month and
multiple ($2) readmissions were observed in more
than one-third of the cohort. Approximately 60% of
readmissions were secondary to noncardiac causes,
and baseline comorbidities played an important role in
delayed readmission.
WHAT IS NEXT? The high readmission burden
observed in this population should be taken into ac-
count so that speciﬁc preventive measures and post-
procedural management to reduce readmission rates
and costs and improve quality of life after TAVR can
be implemented.
TABLE 5 Predictors of Mortality (30 Days to 2 Years) After TAVR
Predictors
Univariable Multivariable
Analysis,
HR (95% CI) p Value
Analysis,
HR (95% CI) p Value
Atrial ﬁbrillation 1.77 (1.24–2.53) 0.002 1.60 (1.11–2.30) 0.012
COPD 1.67 (1.14–2.42) 0.008 1.62 (1.10–2.38) 0.015
eGFR, ml/min* 1.09 (1.01–1.18) 0.036
Hemoglobin at hospital discharge 1.15 (1.01–1.32) 0.040
Acute kidney Injury 1.96 (1.34–2.87) 0.001 1.74 (1.17–2.60) 0.006
Signiﬁcant MR at hospital discharge 2.56 (1.64–3.97) 0.001 2.20 (1.41–3.46) 0.001
Early (#30 days) readmission 1.89 (1.25–2.87) 0.003 1.56 (1.02–2.39) 0.043
*For each decrease of 10 ml/min.
Abbreviations as in Tables 1 through 3.
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1756readmission and associated costs, urgent measures
are needed to reduce such a high readmission burden
and maintain the cost-effectiveness of TAVR.
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